CDK

Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company

Retrieved on: 
Tuesday, April 2, 2024
COVID19, COVID, Trawsfynydd, Pfizer, Drug, Novartis, General partnership, Patient, CYP, Oseltamivir, CDK, Aes, Ritonavir, SARS-CoV-2, Delta, Infection, Viral disease, Omicron, Therapy, OrbiMed, Safety, Pharmacokinetics, Toxicology, Lilly, Bone marrow suppression, CSO, GLP, Mergers and acquisitions, Pharmaceutical industry

Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) along with Nikolay Savchuk, Ph.D. (Torrey Pines)

Key Points: 
  • Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) along with Nikolay Savchuk, Ph.D. (Torrey Pines)
    Companies to host joint webcast, April 2, 2024 at 8:30 a.m.
  • Under the terms of the agreement, Onconova acquired 100% of Trawsfynydd’s outstanding equity interests.
  • These proceeds will be used to advance the Traws’ programs through multiple clinical data catalysts and complete the dose ranging study for narazaciclib.
  • Topline data are expected H2 2024
    Phase 2 study planned to be initiated in H2 2024.

Edgewood Oncology Announces Positive Efficacy Data From Investigator-Sponsored Study of BTX-A51 in Preclinical Models of Liposarcoma

Retrieved on: 
Sunday, April 7, 2024
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Bone marrow, CDK7, MDM2, Apoptosis, BH3, CDK, AML, Dana–Farber Cancer Institute, Patient, LPS, Neoplasm, DNA, Cancer, Liposarcoma, Clinical trial, Azacitidine, CDK9, MCL1, Vaccine

The presentation (Abstract 604), “Targeting casein kinase 1 alpha (CK1alpha) and transcriptional CDKs (CDK7/9) in human liposarcomas,” highlighted findings for BTX-A51 in preclinical human models of LPS.

Key Points: 
  • The presentation (Abstract 604), “Targeting casein kinase 1 alpha (CK1alpha) and transcriptional CDKs (CDK7/9) in human liposarcomas,” highlighted findings for BTX-A51 in preclinical human models of LPS.
  • The data demonstrate that BTX-A51 has preclinical efficacy in treating patient-derived LPS in cell lines and human xenograft models and provides insight into the synergy gained by inhibiting both CK1α and CDK9.
  • “Dedifferentiated liposarcomas (DDLPS) are rare tumors derived from precursors of fat cells which can occur anywhere in the body.
  • Importantly, preliminary in vivo data in an LPS patient-derived xenograft model reveal that BTX-A51 is well-tolerated under conditions that inhibit tumor growth.

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 19, 2024
Research, Mutation, T-cell lymphoma, PD, ARID1A, Webcast, Patient, Lung, CDK, PLK1, Medicine, Clinical trial, CYCC, Cancer, Safety, Cyclacel, Lymphoma

BERKELEY HEIGHTS, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced fourth quarter and full year 2023 financial results and provided a business update.

Key Points: 
  • BERKELEY HEIGHTS, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced fourth quarter and full year 2023 financial results and provided a business update.
  • These include pharmacokinetic (PK), pharmacodynamic (PD), safety and activity data from the dose escalation part of the 065-101 Phase 1/2 study.
  • "We expect to report final Phase 1 results including details on patient genomic profiles at an upcoming medical conference.
  • ( Webcast link )
    For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com .

NiKang Therapeutics Presents the Discovery and Unique Mechanism of Action of a Selective CDK2 Inhibitor NKT3447 at AACR Annual Meeting 2024

Retrieved on: 
Friday, April 5, 2024
Oncology, Health, Other Science, Clinical Trials, Research, Science, Biotechnology, CDK1, Phosphorylation, CDK2, CDK, Patient, Cell cycle, AACR, Therapy, Cancer, Safety, Pharmacokinetics, Cyclin E, Pharmaceutical industry

NKT3447 is an orally bioavailable small molecule CDK2 inhibitor that exhibits high selectivity against CDK1 and other CDKs, prolonged pharmacodynamic effects, and a distinct mechanism of action.

Key Points: 
  • NKT3447 is an orally bioavailable small molecule CDK2 inhibitor that exhibits high selectivity against CDK1 and other CDKs, prolonged pharmacodynamic effects, and a distinct mechanism of action.
  • It downregulates cyclin E and suppresses activating phosphorylation of CDK2 on Thr160.
  • “We are pleased to share the discovery of NKT3447, a highly selective CDK2 inhibitor with unique properties, at the AACR Annual Meeting”, said Zhenhai Gao, Ph.D., co-founder, president, and CEO of NiKang.
  • Discovery of a selective slow-off CDK2 inhibitor NKT3447 with distinct features of suppressing CDK2, downregulating cyclin E, and achieving prolonged pathway inhibition

CDK Bridges Longstanding Gap Between OEM and Dealer Shopping Experiences With Automotive Commerce Collab

Retrieved on: 
Tuesday, March 26, 2024
Technology, Other Retail, Automotive, Automotive Manufacturing, Specialty, Other Automotive, Software, Manufacturing, Retail, Artificial Intelligence, Friction, Documentation, Confusion, International Auto Show, Original equipment manufacturer, Partnership, Trust, Hyundai Motor America, CDK, OEM, Heart, Ecosystem, API, Hyundai, Multimedia, Frustration, Online shopping

View the full release here: https://www.businesswire.com/news/home/20240326270392/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240326270392/en/
    CDK Automotive Commerce Collab (Graphic: Business Wire)
    Thanks to a new initiative from CDK , the industry’s leading retail software provider, a remedy for these pain points is now available.
  • Power Auto Forum during the 2024 New York International Auto Show, the new Automotive Commerce Collab from CDK uses open and universal technology and application programming interfaces (APIs) to better connect OEM and dealer software.
  • The Automotive Commerce Collab is a game changer for everyone.”
    A better retail experience also empowers OEMs to have more control of their brand as consumers move fluidly among the OEM website, dealer website and in-store experience, according to their individual journeys.
  • For more information on the Automotive Commerce Collab initiative, please visit https://www2.cdkglobal.com/commerce-collab .

Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Retrieved on: 
Wednesday, March 20, 2024
Research, General Health, Pharmaceutical, Oncology, Public Relations, Investor Relations, Clinical Trials, Science, Biotechnology, Communications, Practice Management, Other Science, Health, Fulvestrant, Carcinoma, Progression-free survival, Patient, JAMA Oncology, Pharming, Biomarker, CDK, Letrozole, IND, Triple-negative breast cancer, Puma Biotechnology, Cancer, Paclitaxel, Breast cancer, Anastrozole, Tamoxifen, FDA, Food, Pharmaceutical industry

This trial will investigate alisertib in combination with endocrine treatment (consisting of either anastrozole, exemestane, letrozole, fulvestrant or tamoxifen) in chemotherapy-naïve patients with hormone receptor-positive, HER2-negative recurrent or metastatic breast cancer.

Key Points: 
  • This trial will investigate alisertib in combination with endocrine treatment (consisting of either anastrozole, exemestane, letrozole, fulvestrant or tamoxifen) in chemotherapy-naïve patients with hormone receptor-positive, HER2-negative recurrent or metastatic breast cancer.
  • Puma plans to initiate this trial in the second half of 2024.
  • Patients must not have been previously treated with the endocrine treatment that will be given in combination with alisertib in the trial.
  • We look forward to the initiation of the ALISCA-Breast1 trial in the second half of 2024.”
    Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology, said, “We are excited to move forward with the development of alisertib in HER2-negative hormone receptor-positive metastatic breast cancer.

InfluxData Collaborating with AWS to Bring InfluxDB and Time Series Analytics to Developers Around the World

Retrieved on: 
Friday, March 15, 2024
Networks, Internet, Data Management, Technology, Software, Cloud, InfluxDB, Serverless computing, Amazon Web Services, Database, CLI, Information technology, Amazon Virtual Private Cloud, SQL, Amazon, Environment, Data analysis, Organizational founder, OSS, Artificial intelligence, CDK, AWS, Industrial, Behavior, API, Self-management, Veeam, Online shopping

Making InfluxDB a preferred AWS time series database signifies InfluxData’s category leadership and the high-growth market for time series databases to power real-time analytics and artificial intelligence (AI) training models.

Key Points: 
  • Making InfluxDB a preferred AWS time series database signifies InfluxData’s category leadership and the high-growth market for time series databases to power real-time analytics and artificial intelligence (AI) training models.
  • By working with InfluxData, AWS developers now have a simple way to manage and derive value from time series data within the AWS Management Console.
  • In the future, Amazon Timestream for InfluxDB will expand to offer additional InfluxDB versions, including the new InfluxDB 3.0 product line via InfluxDB Community, currently in development.
  • AWS and InfluxData will also collaborate to offer AWS customers additional modules specific to the 3.0 product offering.

Car Pros' Shirley Jones Recognized with "Women Paving the Way" Award

Retrieved on: 
Tuesday, March 19, 2024
Motivation, Woman, Environment, CFO, Knowledge, CDK, Kia, Way, CDK Global, Management

RENTON, Wash., March 19, 2024 /PRNewswire-PRWeb/ -- Car Pros Automotive Group today announced that CFO Shirley Jones has been recognized with a 2024 "Women Paving the Way" award from CDK Global. The award spotlights women who have been a beacon for change for women in the automotive industry. The Paving the Way award campaign from CDK recognizes those in the automotive industry who contribute, connect and collaborate to elevate the role of women.

Key Points: 
  • RENTON, Wash., March 19, 2024 /PRNewswire-PRWeb/ -- Car Pros Automotive Group today announced that CFO Shirley Jones has been recognized with a 2024 "Women Paving the Way" award from CDK Global.
  • The Paving the Way award campaign from CDK recognizes those in the automotive industry who contribute, connect and collaborate to elevate the role of women.
  • Shirley Jones of Car Pros Automotive Group has been recognized with a 2024 "Women Paving the Way" award from CDK Global.
  • "I am so proud of Shirley, and this recognition is so well deserved," said Matthew Phillips, CEO of Car Pros Automotive Group.

Nereus Unveils Revolutionary On-Chain Derivatives Trading Platform on Polygon Network

Retrieved on: 
Monday, March 18, 2024
Nereus, Decentralized finance, CDK, Polygon, Environment, ZK

HONG KONG, March 18, 2024 /PRNewswire/ -- Today, Nereus is excited to announce the launch of its cutting-edge derivatives trading platform on the Polygon network.

Key Points: 
  • HONG KONG, March 18, 2024 /PRNewswire/ -- Today, Nereus is excited to announce the launch of its cutting-edge derivatives trading platform on the Polygon network.
  • Nereus provides a platform that combines the best aspects of centralized and decentralized exchanges, making trading more secure and transparent.
  • This launch marks a significant step forward for derivatives trading, offering a more accessible and efficient option for investors worldwide.
  • By embracing innovation and leveraging the Polygon network, Nereus is leading the way towards a more inclusive and decentralized trading environment.

Nereus Unveils Revolutionary On-Chain Derivatives Trading Platform on Polygon Network

Retrieved on: 
Monday, March 18, 2024
Nereus, Decentralized finance, CDK, Polygon, Environment, ZK

HONG KONG, March 18, 2024 /PRNewswire/ -- Today, Nereus is excited to announce the launch of its cutting-edge derivatives trading platform on the Polygon network.

Key Points: 
  • HONG KONG, March 18, 2024 /PRNewswire/ -- Today, Nereus is excited to announce the launch of its cutting-edge derivatives trading platform on the Polygon network.
  • Nereus provides a platform that combines the best aspects of centralized and decentralized exchanges, making trading more secure and transparent.
  • This launch marks a significant step forward for derivatives trading, offering a more accessible and efficient option for investors worldwide.
  • By embracing innovation and leveraging the Polygon network, Nereus is leading the way towards a more inclusive and decentralized trading environment.